GT101 ni uburyo bwo kuvura uturemangingo tw’umubiri bukozwe muri TIL yagutse kandi ivuguruye iva mu kibyimba cy’umurwayi ubwe. Ubu buryo butangwa hifashishijwe gukuramo ingirangingo z’ikibyimba mu barwayi hanyuma hagakurwamo TIL. Hanyuma TIL yakuwemo izamurwa hakoreshejwe urubuga rwa Grit Bio rukora StemTexp® hanyuma isubizwe mu barwayi kugira ngo irwanye ibibyimba.
Ku wa 2024Inama ngarukamwaka y’Umuryango w’Abanyamerika wita ku ndwara za kanseri (ASCO),Amakuru yatanzwe ku barwayi 14 ba kanseri ikomeye bitabiriye ubushakashatsi bwa GT101. Igerageza ryakozwe hagamijwe gusuzuma DLT no kugaragaza umutekano wa GT101 ku barwayi ba kanseri ikomeye bipimirwa n'ingaruka mbi zo mu rwego rwa ≥ 3 ku ndwara (TEAEs). Ingingo za kabiri zari ukureba ibipimo by'imikorere birimo igipimo rusange cyo gusubiza (ORR), igipimo cyo kurwanya indwara (DCR), kubaho nta guhindagurika (PFS), igihe cyo gusubiza (DOR), n'igihe cyo kubaho muri rusange (OS) nk'uko bivugwa na RECIST v1.1.
Ibisubizo: Guhera ku ya 10 Ugushyingo 2023, itsinda ry'abarwayi 14 bahawe ubuvuzi bafite imyaka 46.9 n'imibare 2.6 y'ubuvuzi bwabanje. Nyuma yo kuvurwa hakoreshejwe uburyo busanzwe bwa FC-based lymphodepletion, abarwayi batewe GT101 ku gipimo cya ≥ 5×109 uturemangingo 3.7×1010, hagakurikiraho guhabwa IL-2 ku gipimo kinini. Inyinshi mu ndwara zagaragaye zo mu cyiciro cya ≥ 3 zari zijyanye n'uburyo bwo kuvura bwa FC na IL-2, harimo kugabanuka kw'umubare wa limfositike, kugabanuka kw'umubare w'uturemangingo tw'amaraso twera, kugabanuka kw'umubare wa neutrophil, kugabanuka k'amaraso, pyrexia no kugabanuka kw'umubare wa platelet. Inyinshi muri izi ndwara za AE zakize mu minsi 14, mu gihe nke zagabanutse zikagera kuri ≤ 2 mu byumweru 4. Mu barwayi 14 biyandikishije mu bimenyetso bitandukanye (kanseri y'uturemangingo duto-ibihaha, melanoma, kanseri y'inkondo y'umura), ORR yari 35.7%. By’umwihariko, amanota 4 (28.6%) yari afite igisubizo cy’igice cy’umuti (PR), amanota 1 (7.1%) yari afite igisubizo cyuzuye (CR), naho amanota 8 (57.1%) yari afite indwara idahinduka (SD) nk’igisubizo cyiza. Umubare umwe wari ufite intambwe itaramenyekana y’indwara (PD). Ikigaragara ni uko mu barwayi 11/14 barwaye kanseri y’inkondo y’umura, ORR yari 45.5% (5/11) aho amanota 4 (36.4%) yari afite PR na amanota 1 (9.1%) yari afite CR. Kurwanya indwara byagaragaye mu byiciro 10/11 (90.9%), naho ikigereranyo cya PFS cyari amezi 4.2 kuri iri tsinda. Umurwayi wa CR yakurikiranwe igihe kirekire kandi igihe CR na PFS (byagereranyijwe na Kaplan-Meier) cyari ibyumweru 24 n’ibyumweru 36, uko bikurikirana. Nyuma yo guterwa GT101, uturemangingo twa T twagutse cyane mu maraso yo mu mpande z'abarwayi bose bafite impuzandengo ya Tmax iminsi 6.83 n'iminsi 15.9.
Umwanzuro: Mu bushakashatsi bwa GT101 Icyiciro cya 1, nta ndwara za SAE na DLT zijyanye n'ubuvuzi zagaragaye. Ku barwayi bafite ibibyimba bikomeye cyangwa byavuwe mbere, GT101 yagaragaje umutekano uhamye hakurikijwe uburyo bwo kuvura indwara ya lymphodepletion na IL-2 ikoreshwa ku gipimo kinini ndetse n'imiterere myiza y'ubuvuzi, cyane cyane muri kanseri y'inkondo y'umura, hamwe na ORR ishimishije kandi igakomeza igihe kirekire.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Amareferensi
1.https://www.grit-bio.com/newsinfo/4620292.html
2.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2548
Igihe cyo kohereza: Ukuboza-20-2024